Anavex Life Sciences Corp AVXL

Healthcare Biotechnology

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.

NDAQ:AVXL - Post by User

Anavex Life Sciences Corp

<< Previous

Bullboard Posts

Post by hoffbagon Nov 25, 2023 5:20pm

181 Views

Post# 35753031

Not a lot of respect here….

For their data. Seems like everyone is doubting efficacy. But the approved products are NG also? Well if the pharma gods and the FDA are wrong and Anavex gets EMA approval there are going to be a lot of upset apple carts...
Sometimes you gotta cheer for an underdog!

<< Previous

Bullboard Posts

Rich TV Live's Stocks to Watch this week (May 3, 2024)